Intranasal Glutathione in Parkinson's Disease

elderly man using nasal spray

Published November 17, 2010

About the Study

Parkinson's disease (PD) is considered a progressive and irreversible neurodegenerative disease. Current therapies improve disease symptoms, however, none alter the underlying degenerative course. Research suggests the loss of brain glutathione, a powerful antioxidant, is one of the earliest changes to occur in the brain of PD patients and the magnitude of glutathione depletion parallels the severity of PD. This study will look at the use of intranasal glutathione in PD patients to determine safety, tolerability, and impact on PD symptoms.


Project Overview



Study area


Principal investigator

Laurie Mischley, ND

Project period

January 2010 – December 2014

Completed date (for sorting)

Wednesday, April 30, 2014